Stoke Therapeutics (STOK) Net Income towards Common Stockholders (2018 - 2026)

Stoke Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$50.0 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 144.3% year-over-year to -$50.0 million in Q1 2026; TTM through Mar 2026 was -$174.3 million, a 478.76% decrease from a year earlier, with the FY2025 full-year figure at -$204.3 million, down 67.55% from the prior year.
• Net Income towards Common Stockholders rose to -$50.0 million in Q1 2026 per STOK's latest filing, from -$62.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $112.9 million in Q1 2025 and bottomed at -$162.8 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$27.2 million (2023), against an average of -$36.4 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 527.99% in 2025; the steepest drop was 323.5% in 2025.
• Year by year, Net Income towards Common Stockholders stood at -$124.5 million in 2022, then slumped by 30.69% to -$162.8 million in 2023, then surged by 90.94% to -$14.7 million in 2024, then tumbled by 323.5% to -$62.4 million in 2025, then rose by 19.91% to -$50.0 million in 2026.
• Per Business Quant, the three latest STOK Net Income towards Common Stockholders figures stand at -$50.0 million (Q1 2026), -$62.4 million (Q4 2025), and -$38.3 million (Q3 2025).